New startup ideas · Health and bio · Healthcare and bio

startup idea

Plasmidrun

GMP plasmid and mRNA batches ordered by API, no CDMO negotiation.

Plasmidrun runs small automated GMP suites and exposes them as an API: a small biotech posts a sequence, a batch size and a target release date, and gets back a scheduled slot, a price and, weeks later, a released batch with its full electronic batch record.

Infrastructure and APIs
Small business
$10-100B market
Platform others build on
Global from day one

4/5

venture judge

similar startups, last 2 years (1 all-time)

97%

of 4 nearest real companies still alive

yes

1 matching federal grants and programs

Direction supported by government programs and grants

Test it before you build it

$2,300 · 6 weeks · 25 prospects

Prove that 5 of 20 seed-stage vaccine and cell therapy teams will prepay for a research-grade plasmid run ordered through a self-serve quote page, brokered by hand behind the scenes, for under $3,000 in 6 weeks

1Focus group: who and where

The founder or de facto head of CMC at a US biotech under 20 people, seed to Series A, in gene therapy, mRNA vaccines or cell therapy, currently ordering research-grade plasmid by email from Aldevron, GenScript or VectorBuilder and sitting 12-24 months from an IND filing

where to find 25 · LinkedIn Sales Navigator filtered to Biotechnology, 1-20 employees, US, titles Founder or CEO or Head of CMC, keyword plasmid or mRNA or AAV; the YC company directory filtered to bio; the Bits in Bio Slack; attendee and exhibitor lists from the ASGCT Annual Meeting; 25 reachable in a week

2Sell first, build later

A research-grade plasmid batch at a firm price with a guaranteed ship date 3 weeks from payment, delivered with a standardized electronic batch report; plus a reservable GMP slot for a named 2027 quarter at a price locked now

the ask · $4,000 to $8,000 per research-grade run depending on scale, invoiced 100 percent up front; GMP slot reserved with a $5,000 refundable deposit against a $150,000 to $400,000 batch

a real yes · A real yes is a paid invoice before any work starts or a signed slot agreement with the deposit wired. Compliments, 'send me the deck', unpaid sample requests and intros to a procurement person count for nothing

3Small experiments

The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.

1. Procurement pain interviews
$150 · 12 days
Book 15 calls from the Sales Navigator list with a cold email that asks one question: how long did your last plasmid order take from quote to material. Walk through their last order: lead time, price, number of emails, what the tech transfer cost them. One founder runs all 15 in weeks 1-2.
keep going if · 10 of 15 report 6-plus weeks quote-to-material or 20-plus emails per order, and 8 of 15 ask to see the price sheet before the call ends
2. Fake-door instant quote page
$400 · 10 days
One page: paste a sequence, pick a batch size, get a firm price and a guaranteed ship date in 60 seconds, research-grade now, GMP slots opening later. The quote engine is a founder answering within the hour from a pre-built price table. Post it in Bits in Bio and send to the full prospect list.
keep going if · 12 real sequences submitted for quotes in 14 days, at least 4 from teams outside the interview list
3. Concierge brokered run prepaid
$1,500 · 28 days
For quote requesters, sell a research-grade plasmid batch at a fixed price with a fixed ship date, invoiced 100 percent up front. Fulfill by subcontracting an existing manufacturer with spare capacity, with the founders managing the order and delivering a normalized batch report in Plasmidrun's format. Margin can be zero; the test is whether they prepay a fixed-price fixed-date offer from a no-name vendor.
keep going if · 5 of 12 quote requesters pay the full invoice before work starts
4. GMP slot deposit pre-sale
$200 · 14 days
Offer the 5 buyers and the most IND-advanced interviewees a reserved GMP production slot for a named quarter of 2027 at a locked price, secured by a refundable deposit and a one-page slot agreement signed by both parties. This tests whether the upgrade path from research-grade to clinical-grade holds money.
keep going if · 3 signed slot agreements with $5,000 deposits paid

4Collect a deposit up front

Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.

$5,000

per prospect, refundable

how · Research-grade runs invoiced 100 percent up front via Stripe Invoicing or ACH; GMP slots held by a $5,000 refundable deposit under a one-page slot reservation agreement signed by the buyer's CEO set up: Stripe Invoicing ↗

what it reserves · A named GMP production window in a specific 2027 quarter, a locked batch price, and first-in-line tech transfer using the sequence and process data from their research-grade run

refund · Refunded in full if Plasmidrun's suite is not GMP-qualified 60 days before the reserved window, or on written cancellation up to 90 days before the slot

target · 5 prepaid research-grade runs and 3 GMP slot deposits from 25 prospects within 42 days

Go: build it if

5 or more fully prepaid research runs at a gross price of $4,000-plus and 3 or more $5,000 slot deposits: small teams will buy manufacturing as an endpoint and prepay for future GMP capacity

Kill: stop if

Fewer than 8 sequences submitted to the quote page, or fewer than 2 prepaid runs, or every buyer demands net-60 terms and a site audit before paying: the buyer behaves like a pharma procurement department, and the self-serve API premise fails

Would you run this test?

One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.

Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.

Scorecard

One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.

Idea Score, 0-100 · raw 52.3 x 1.64

Open

competition: more crowded than 6% of ideas · headwind x0.97

+0.8

government priorities, secondary (1 matching grants)

Trend

Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.

Entrants 2025-26 vs 2023-24 (similar companies)23
Rounds announced 2025+ in the sector68
Sector direction (live batch)100
2026 trend analyst25

Demand

Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.

YC asks for it (current RFS: idea / sector)30
Someone already pays (similar companies, recent / all-time)8
Operator judge: real pain75
Founders' yes-rate in decks27

100x potential

Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.

Venture judge75
Market size axis67
Moat axis80
Technologist judge100

Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were gmp, plasmid, mrna, batches, ordered, cdmo, negotiation, automated.

The idea in full

What: Plasmidrun runs small automated GMP suites and exposes them as an API: a small biotech posts a sequence, a batch size and a target release date, and gets back a scheduled slot, a price and, weeks later, a released batch with its full electronic batch record. Closed-loop process control models trained on every run set the parameters, which is what lets a two-person team order clinical-grade material without a tech transfer project. The build is capital-heavy, the regulatory burden is full cGMP, and first revenue comes from research-grade runs in year one while the GMP suite qualifies.
Why now: The radar shows the demand side collapsing to tiny teams that still need real material: Omanta (yc S26) is literally a research lab for one, TareBio (yc S26) promises vaccines for any cancer or infection in weeks, and AbInitio Bio (yc X26) is building an intelligence layer for drug manufacturing, while Ambrosia Biosciences raised a $100M Series B on 2026-03-31, so capital exists for the physical layer.
Wedge: first customer and entry point: Seed-stage vaccine and cell therapy teams buying research-grade plasmid today by email: same molecule, same API, one week turnaround, then upgrade them to the GMP slot when they hit IND.
Path to 100x: Biologics contract manufacturing is a $10 to 100B market that is priced and scheduled for large pharma, so small teams wait months and overpay. The distribution moat is being the default execute button inside the design tools and AI protein and sequence platforms those teams already use, so every new design tool that ships a Plasmidrun endpoint routes its users' first clinical material here, and the process-control model gets better with each batch.
Ceiling: Suite capacity is physical, so growth is gated by capex per additional site and a competitor with cheaper capital can copy the API without copying anything hard.
Closest real companies, as the generator saw them: AbInitio Bio sells software intelligence into other people's plants; Plasmidrun owns the plant and sells capacity as an endpoint. Omanta automates discovery-scale experiments, not clinical-grade batch release.
Main risk: GMP qualification and deviation handling swallow the automation advantage, and Plasmidrun ends up a normal CDMO with worse margins and a nicer website.

Five judges

Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).

Venture investor
4/5
Being the default execute button inside design tools is a distribution moat on a $10-100B market, though capex per suite gates growth.
Bootstrapper
1/5
Automated GMP suites under full cGMP are capex plus qualification years, far past what a two-person team can fund.
Operator
4/5
Seed biotechs already pay six figures and wait months for plasmid slots, and they order by email today, so the API replaces an existing invoice.
Technologist
5/5
Automated GMP suites with closed-loop process control trained on every run is cGMP hardware plus models that improve batch by batch.
Risk
3/5
Full cGMP footing is owned, but capacity sits in single suites and the distribution moat depends on third-party design tools shipping a Plasmidrun endpoint.
trends
2/5
GMP-by-API depends on no regulation or protocol dated 2025-2026; the cited $100M Series B funds a competitor's layer, not this window.

Similar startups in the directory

Companies whose pitch matches most of the idea's terms (gmp, plasmid, mrna, batches, ordered, cdmo, negotiation, automated): 1 all-time, 0 from the last two years. Same matching as Idea Check.

Flowspaceyc S17 · 2017 · Commerce and marketplacesalive
The operating system powering ecommerce fulfillment

Run this as an Idea Check →

The generator's reference companies

Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.

Public money in this direction

US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.

grants and programs matching the idea

1127

startup-relevant grants in Healthcare and bio

$590M

awarded in the sector, tracked

130

opportunities open now in the sector

Rapid Control and Assessment of Dissolved Gas Signals on Tissue Function andDisease.awardmedium relevance
NIH / NIGMS · STTR phase I · $307K · posted 2025-09-04

All public money by sector →

Market signal

What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.

Healthcare and bio · 130 → 118 → 216 → 173 → 71 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 21 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 37 rewrote their pitch

Healthcare and bio: companies, trend and grants →

Design attributes

The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.

Buyer: Small business
Business model: Infrastructure and APIs
Path to 100x: Platform others build on
Market size: $10-100B market
Capital intensity: Capital-heavy (hardware, bio, infra)
Speed to revenue: Revenue in 1-3 years
Technical depth: Deep tech: ML, hardware, bio
Go-to-market: Self-serve
Moat: Distribution moat
Geography: Global from day one
Regulation: Heavily regulated
Vibe: Hot space